Pubblicazioni scelte

---

1) Tornatore L, Sandomenico A, Raimondo D, Low C, Rocci A, Tralau-Stewart C, Capece D, D'Andrea D, Bua M, Boyle E, van Duin M, Zoppoli P, Jaxa-Chamiec A, Thotakura AK, Dyson J, Walker BA, Leonardi A, Chambery A, Driessen C, Sonneveld P, Morgan G, Palumbo A, Tramontano A, Rahemtulla A, Ruvo M, Franzoso G. Cancer-Selective Targeting of the NF-κB Survival Pathway with GADD45β/MKK7 Inhibitors. Cancer Cell. 2014, PMID: 28898681; PMCID: PMC5629036.
2)Focà G, Iaccarino E, Focà A, Sanguigno L, Untiveros G, Cuevas-Nunez M, Strizzi L, Leonardi A, Ruvo M, Sandomenico A. Development of conformational antibodies targeting Cripto-1 with neutralizing effects in vitro. Biochimie. 2019 PMID: 30703478.
3)Selis F#, Sandomenico A#, Cantile M, Sanna R, Calvanese L, Falcigno L, Dell'Omo P, Esperti A, De Falco S, Focà A, Caporale A, Iaccarino E, Truppo E, Scaramuzza S, Tonon G, Ruvo M. Generation and testing of engineered multimeric Fabs of trastuzumab. Int J Biol Macromol. 2020 PMID: 32941911.
4)Esposito CL, Autiero I, Sandomenico A, Li H, Bassal MA, Ibba ML, Wang D, Rinaldi L, Ummarino S, Gaggi G, Borchiellini M, Swiderski P, Ruvo M, Catuogno S, Ebralidze AK, Kortylewski M, de Franciscis V, Di Ruscio A. Targeted systematic evolution of an RNA platform neutralizing DNMT1 function and controlling DNA methylation. Nat Commun. 2023 PMID: 36609400; PMCID: PMC9823104.
5) Oliver A, Landi N, Iaccarino E, Ragucci S, Cantile M, Ronca R, Annunziata S, Barisciano G, Sanna R, Pedone PV, Di Maro A, Sandomenico A*, Ruvo M*. A new trastuzumab-ageritin-based immunotoxin that specifically kills breast cancer cells. Int J Biol Macromol. 2026 PMID: 42320816.